New Delhi: Drug main Roche India on Monday launched its first batch of antibody cocktail – Casirivimab and Imdevimab – towards COVID-19 in India at Rs 59,750 per dose.
In a press release, the corporate stated: “Each of the 1,200 mg dose of the drug contains 600 mg of Casirivimab and 600 mg of Imdevimab. The price of each dose will be Rs 59,750. The maximum retail price for the multi-dose pack will be Rs 1,19,500. Notably, each pack can treat two patients.”
According to studies, the antibody cocktail just lately obtained an Emergency Use Authorisation (EUA) in India by the Central Drugs Standards Control Organisation (CDSCO), Earlier, it has additionally obtained a EUA within the US and a number of other EU international locations. It is to be famous that the drug was given to then US President Donald Trump when he contracted COVID-19 final yr.
Roche, in a joint assertion with Cipla additional introduced that the drug can be marketed in India by Cipla and the second batch can be made out there by mid-June.
“The first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit two lakh patients as each of the one lakh packs that will be available in India offers treatment for two patients, ” the joint assertion issued by Cipla and Roche stated.
The antibody cocktail is to be administered for the remedy of gentle to average COVID-19 in adults and pediatric sufferers (12 years of age or older, weighing no less than 40 kg) who’re confirmed to be contaminated with SARS-COV2 and who’re at excessive danger of creating extreme COVID-19 illness and don’t require oxygen.
The cocktail drug has been proven to assist these high-risk sufferers earlier than their situation worsens, decreasing the chance of hospitalisation and fatality by 70 per cent.
(With ANI Inputs)
Check out beneath Health Tools-
Calculate Your Body Mass Index ( BMI )